Key result
Empagliflozin reduces cardiomyocyte aging and improves function in diabetic models via FOXO1-mediated ANGPTL4 downregulation.
Why the study?
Whether SGLT2 inhibitors improve cardiomyocyte function through the alleviation of aging, and their mechanism of action on the FOXO1-ANGPTL4 pathway, was unknown.
Population
DCM mice induced by T2DM and AC16 human cardiomyocytes stimulated with HG and PA
Comparison
SGLT2i treatment vs control
Design
Preclinical in vivo and in vitro mechanistic study
Authors
Loading...
Hypothesis-generating in diabetic cardiomyopathy models; leaves open clinical translation of the FOXO1-ANGPTL4 pathway.
p-value: p=<0.05
SGLT2 inhibitors mitigate pathological aging of cardiomyocytes and improve cardiac function in diabetic cardiomyopathy models by regulating the FOXO1-ANGPTL4 pathway.
Wen et al. (2024) studied Diabetic cardiomyopathy. Empagliflozin vs. Vehicle/Saline (in vivo); Low glucose (in vitro) was evaluated on Cellular senescence phenotype and cardiac function (p=<0.05). Empagliflozin ameliorated pathological aging of cardiomyocytes and improved cardiac function in diabetic cardiomyopathy models by downregulating ANGPTL4 transcription via the FOXO1 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: